Evidence map›Paper›PMID 40595451›Full record

ArticleCell death & disease2025

Targeting the TRIM14/USP14 axis enhances radiotherapy efficacy by inducing GPX4 degradation and disrupting ferroptotic defense in HCC.

Xin Yue, Zhen Xiang, Yang Yi, Xuecen Wang, Weilin Zhou, Weijian Wu, Wenjing Qin, Yuxuan Zhao, Xianzhang Bu, Zhenwei Peng

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. The TRIM14-KIF1B Axis Drives Renal Injury in Diabetic Nephropathy Through TLR4/NF-κB Pathway Modulation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin Yue *Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. yuex2504@jnu.edu.cn.ORCID http://orcid.org/0000-0003-4202-3772
Zhen Xiang *Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yang Yi *Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xuecen Wang *Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Weilin ZhouState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Weijian WuState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Wenjing QinState Key Laboratory of Bioactive Molecules and Druggability Assessment, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Yuxuan ZhaoState Key Laboratory of Bioactive Molecules and Druggability Assessment, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Xianzhang BuState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China. phsbxzh@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-3015-6634
Zhenwei PengDepartment of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. pzhenw@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-0617-3805

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82272743National Natural Science Foundation of China (National Science Foundation of China) 82373209National Natural Science Foundation of China (National Science Foundation of China) 82373713National Natural Science Foundation of China (National Science Foundation of China) 82473251
6 · The paper itself

Abstract

Radiation resistance constitutes a formidable impediment in the treatment paradigm for hepatocellular carcinoma (HCC). Deubiquitinases (DUBs) exhibit notable efficacy in modulating cellular responses to stress and exogenous interventions, endowed with the critical trait of being targetable, thus facilitating the execution of precise therapeutic strategies. Here, we demonstrate that broad-spectrum inhibition of thiol hydrolase-type DUBs markedly augments radiotherapy sensitivity in HCC cells. Based on this, via CRISPR-based screening, we identified USP14 as the principal DUB orchestrating radioresistance. Ferroptosis emerged as a pivotal form of radiation-induced cell death, with our study singularly illustrating that USP14 is instrumental in directing cellular defenses against ferroptosis via the targeting and stabilization of glutathione peroxidase (GPX4). Mechanistically, we found that radiation triggers the assembly of Tripartite motif-containing protein 14 (TRIM14) at the GPX4 locus, subsequently recruiting USP14. The TRIM14/USP14 complex facilitates the excision of pronounced K48-linked polyubiquitination at lysine residues 48 or 118 on GPX4, thereby preserving GPX4's structural integrity and antioxidative function to counteract ferroptosis. Intriguingly, TRIM14-mediated GPX4 stabilization is further amplified in radioresistant HCC, and subsequent radiation enables USP14-dependent blockade of GPX4 degradation. Consequently, pharmacological inhibition of USP14 substantially increases the susceptibility of HCC cells, thereby sensitizing patient-derived xenograft (PDX) tumors to radiotherapy. Concurrently, we explored the abscopal effect of radiotherapy and revealed that targeting USP14-enhanced ferroptosis augments antitumor immune responses post-radiation, suggesting a strategy to sustain therapeutic efficacy. In conclusion, our study uncovers the TRIM14/USP14 axis as a critical suppressor of radiation-induced ferroptosis and an actionable target to overcome radioresistance in HCC. These findings provide mechanistic insights and a translational framework for improving radiotherapy outcomes.

Indexed as

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseUbiquitin ThiolesteraseAnimalsCell Line, TumorHumansMiceMice, NudeProteolysisRadiation ToleranceUbiquitinationPhospholipid Hydroperoxide Glutathione PeroxidaseUbiquitin ThiolesteraseUSP14 protein, human

Identifiers

PMID40595451
PMCPMC12219831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.